BRAF p.V600E

About

Biomarker type: Somatic variant

Gene context: BRAF

HGVS.p: NP_004324.2:p.Val600Glu

Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (2) BRAF p.V600E Melanoma Atezolizumab, Cobimetinib, Vemurafenib
EMA (2) FDA (4) BRAF p.V600E Melanoma Binimetinib, Encorafenib
EMA (2) FDA (4) BRAF p.V600E Non-Small Cell Lung Cancer Binimetinib, Encorafenib
EMA (2) FDA (4) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib
EMA (1) FDA (2) BRAF p.V600E Melanoma Cobimetinib, Vemurafenib
EMA (1) FDA (2) BRAF p.V600E Melanoma Dabrafenib
EMA (4) FDA (8) BRAF p.V600E Melanoma Dabrafenib, Trametinib
EMA (2) FDA (4) BRAF p.V600E Non-Small Cell Lung Cancer Dabrafenib, Trametinib
FDA (4) BRAF p.V600E Anaplastic Thyroid Cancer Dabrafenib, Trametinib
FDA (4) BRAF p.V600E Any solid tumor Dabrafenib, Trametinib
EMA (1) FDA (4) BRAF p.V600E Low-Grade Glioma Dabrafenib, Trametinib
EMA (1) FDA (2) BRAF p.V600E Melanoma Trametinib
EMA (1) FDA (2) BRAF p.V600E Melanoma Vemurafenib
FDA (2) BRAF p.V600E Erdheim-Chester Disease Vemurafenib
EMA (1) FDA (2) BRAF p.V600E Low-Grade Glioma Tovorafenib
EMA (2) FDA (2) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
EMA (1) BRAF p.V600E High-Grade Glioma Dabrafenib, Trametinib
FDA (2) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Irinotecan
EMA (1) BRAF p.V600E Differentiated Thyroid Gland Carcinoma Dabrafenib, Trametinib